Wolfe Research Initiates Coverage On Myriad Genetics with Outperform Rating
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research analyst Doug Schenkel has initiated coverage on Myriad Genetics (NASDAQ:MYGN) with an Outperform rating, indicating a positive outlook for the company's stock.

December 13, 2023 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wolfe Research analyst Doug Schenkel has started coverage on Myriad Genetics with an Outperform rating, suggesting a bullish stance on the stock.
Analyst ratings, especially those that initiate coverage, can have a significant impact on a stock's performance in the short term. An Outperform rating usually suggests that the analyst believes the stock will perform better than the market or its sector, which can lead to increased investor interest and potentially a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100